News

Natco Pharma launches drug in the US for the treatment of adult patients with multiple myelomaThe capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of last therapy, Natco Pharma said.By Shloka Badkar  March 3, 2026, 12:21:52 PM IST (Published)2 Min ReadNatco Pharma Ltd. on Tuesday, March 3, said it has, along with its partner Breckenridge Pharmaceutical, launched Pomalidomide capsules, a generic version of Pomalyst by Celgene in the US market.

The capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of last therapy, the company said.

It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma, it said.

The product is available in 1mg, 2mg, 3mg and 4mg strengths and is distributed primarily via specialty pharmacies and clinics.

The capsules had estimated sales of$3.2 billion in the US for 12 months ending September 2025, as per industry sales data, the company said.

Based on the information made available by the US Food and Drug Administration, Natco Pharma said it believes it has 180 days of shared exclusivity.

The company's vice-chairman and CEO Rajeev Nannapeneni said the launch strengthens the company's oncology and specialty portfolio in the US.

Shares of Natco Pharma ended the previous session 3.4% lower at 955 apiece. The stock has gained 11.6% in the past month.

Also Read: Tata Motors CV clarifies on reports of Indonesia order being put on hold; Here's what it saidContinue ReadingTagsNatco Pharmashare market today